374 related articles for article (PubMed ID: 27708221)
21. RN181 is a tumour suppressor in gastric cancer by regulation of the ERK/MAPK-cyclin D1/CDK4 pathway.
Wang S; Wang X; Gao Y; Peng Y; Dong N; Xie Q; Zhang X; Wu Y; Li M; Li JL
J Pathol; 2019 Jun; 248(2):204-216. PubMed ID: 30714150
[TBL] [Abstract][Full Text] [Related]
22. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
[No Abstract] [Full Text] [Related]
23. Vaccinia-related kinase 1 promotes hepatocellular carcinoma by controlling the levels of cell cycle regulators associated with G1/S transition.
Lee N; Kwon JH; Kim YB; Kim SH; Park SJ; Xu W; Jung HY; Kim KT; Wang HJ; Choi KY
Oncotarget; 2015 Oct; 6(30):30130-48. PubMed ID: 26375549
[TBL] [Abstract][Full Text] [Related]
24. Ara-c induces cell cycle G1/S arrest by inducing upregulation of the INK4 family gene or directly inhibiting the formation of the cell cycle-dependent complex CDK4/cyclin D1.
Sun F; Li N; Tong X; Zeng J; He S; Gai T; Bai Y; Liu L; Lu K; Shen J; Han M; Lu C; Dai F
Cell Cycle; 2019 Sep; 18(18):2293-2306. PubMed ID: 31322047
[TBL] [Abstract][Full Text] [Related]
25. TRIM31 is upregulated in hepatocellular carcinoma and promotes disease progression by inducing ubiquitination of TSC1-TSC2 complex.
Guo P; Ma X; Zhao W; Huai W; Li T; Qiu Y; Zhang Y; Han L
Oncogene; 2018 Jan; 37(4):478-488. PubMed ID: 28967907
[TBL] [Abstract][Full Text] [Related]
26. CACYBP Enhances Cytoplasmic Retention of P27
Lian YF; Huang YL; Zhang YJ; Chen DM; Wang JL; Wei H; Bi YH; Jiang ZW; Li P; Chen MS; Huang YH
Theranostics; 2019; 9(26):8392-8408. PubMed ID: 31754404
[TBL] [Abstract][Full Text] [Related]
27. JMJD6 promotes hepatocellular carcinoma carcinogenesis by targeting CDK4.
Wan J; Liu H; Yang L; Ma L; Liu J; Ming L
Int J Cancer; 2019 May; 144(10):2489-2500. PubMed ID: 30125344
[TBL] [Abstract][Full Text] [Related]
28. RASSF7 promotes cell proliferation through activating MEK1/2-ERK1/2 signaling pathway in hepatocellular carcinoma.
Zhang M; Li Q; Zhang L; Wang Y; Wang L; Li Q; He T; Wan B; Wang X
Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):73-79. PubMed ID: 29729697
[TBL] [Abstract][Full Text] [Related]
29. The LINC01138 drives malignancies via activating arginine methyltransferase 5 in hepatocellular carcinoma.
Li Z; Zhang J; Liu X; Li S; Wang Q; Di Chen ; Hu Z; Yu T; Ding J; Li J; Yao M; Fan J; Huang S; Gao Q; Zhao Y; He X
Nat Commun; 2018 Apr; 9(1):1572. PubMed ID: 29679004
[TBL] [Abstract][Full Text] [Related]
30. 20(S)-Ginsenoside Rh2 suppresses proliferation and migration of hepatocellular carcinoma cells by targeting EZH2 to regulate CDKN2A-2B gene cluster transcription.
Li Q; Li B; Dong C; Wang Y; Li Q
Eur J Pharmacol; 2017 Nov; 815():173-180. PubMed ID: 28928088
[TBL] [Abstract][Full Text] [Related]
31. TRIM59 promotes tumor growth in hepatocellular carcinoma and regulates the cell cycle by degradation of protein phosphatase 1B.
Ying H; Ji L; Xu Z; Fan X; Tong Y; Liu H; Zhao J; Cai X
Cancer Lett; 2020 Mar; 473():13-24. PubMed ID: 31875525
[TBL] [Abstract][Full Text] [Related]
32. PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
Lin CC; Chang TC; Wang Y; Guo L; Gao Y; Bikorimana E; Lemoff A; Fang YV; Zhang H; Zhang Y; Ye D; Soria-Bretones I; Servetto A; Lee KM; Luo X; Otto JJ; Akamatsu H; Napolitano F; Mani R; Cescon DW; Xu L; Xie Y; Mendell JT; Hanker AB; Arteaga CL
Nat Commun; 2024 Mar; 15(1):2287. PubMed ID: 38480701
[TBL] [Abstract][Full Text] [Related]
33. Targeting ODC1 inhibits tumor growth through reduction of lipid metabolism in human hepatocellular carcinoma.
Choi Y; Oh ST; Won MA; Choi KM; Ko MJ; Seo D; Jeon TW; Baik IH; Ye SK; Park KU; Park IC; Jang BC; Seo JY; Lee YH
Biochem Biophys Res Commun; 2016 Sep; 478(4):1674-81. PubMed ID: 27592554
[TBL] [Abstract][Full Text] [Related]
34. Estrogen-related receptor γ is upregulated in liver cancer and its inhibition suppresses liver cancer cell proliferation via induction of p21 and p27.
Kim JH; Choi YK; Byun JK; Kim MK; Kang YN; Kim SH; Lee S; Jang BK; Park KG
Exp Mol Med; 2016 Mar; 48(3):e213. PubMed ID: 26940882
[TBL] [Abstract][Full Text] [Related]
35. Loss of miR-1258 contributes to carcinogenesis and progression of liver cancer through targeting CDC28 protein kinase regulatory subunit 1B.
Hu M; Wang M; Lu H; Wang X; Fang X; Wang J; Ma C; Chen X; Xia H
Oncotarget; 2016 Jul; 7(28):43419-43431. PubMed ID: 27270326
[TBL] [Abstract][Full Text] [Related]
36. Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5.
Tian Y; Yang W; Yang R; Zhang Q; Hao L; Bian E; Yang Y; Huang X; Wu Y; Zhang B
Toxicol Appl Pharmacol; 2022 Jan; 435():115829. PubMed ID: 34919946
[TBL] [Abstract][Full Text] [Related]
37. CDCA7L promotes hepatocellular carcinoma progression by regulating the cell cycle.
Tian Y; Huang C; Zhang H; Ni Q; Han S; Wang D; Han Z; Li X
Int J Oncol; 2013 Dec; 43(6):2082-90. PubMed ID: 24141559
[TBL] [Abstract][Full Text] [Related]
38. RBP-J-interacting and tubulin-associated protein induces apoptosis and cell cycle arrest in human hepatocellular carcinoma by activating the p53-Fbxw7 pathway.
Wang H; Yang Z; Liu C; Huang S; Wang H; Chen Y; Chen G
Biochem Biophys Res Commun; 2014 Nov; 454(1):71-7. PubMed ID: 25445601
[TBL] [Abstract][Full Text] [Related]
39. The activation of MEK/ERK signaling pathway by bone morphogenetic protein 4 to increase hepatocellular carcinoma cell proliferation and migration.
Chiu CY; Kuo KK; Kuo TL; Lee KT; Cheng KH
Mol Cancer Res; 2012 Mar; 10(3):415-27. PubMed ID: 22241220
[TBL] [Abstract][Full Text] [Related]
40. The upregulation of stromal antigen 3 expression suppresses the phenotypic hallmarks of hepatocellular carcinoma through the Smad3-CDK4/CDK6-cyclin D1 and CXCR4/RhoA pathways.
Zhao M; Wang Y; Zhang Y; Li X; Mi J; Wang Q; Geng Z; Zuo L; Song X; Ge S; Zhang Z; Tang M; Li H; Wang Z; Jiang C; Su F
BMC Gastroenterol; 2022 Aug; 22(1):378. PubMed ID: 35941537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
